Viewing Study NCT01449058

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:00 AM
Ignite Modification Date: 2026-05-29 @ 10:45 AM
Study NCT ID: NCT01449058
Status: COMPLETED
Last Update Posted: 2017-10-02
First Post: 2011-10-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Sponsor: Array BioPharma
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced and Selected Solid Tumors View
None AML View
None High Risk and Very High Risk MDS View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced solid tumor, View
None AML View
None high risk and very high risk MDS View
None dose escalation, View
None RAS/BRAF mutation, View
None PI3K inhibitor, View
None MEK inhibitor, View
None BYL719, View
None MEK162 View